Ascendis Pharma A/S (NASDAQ:ASND) Given New $200.00 Price Target at Cantor Fitzgerald
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective lifted by stock analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 31.05% from the […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective lifted by stock analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 31.05% from the […]
